NSV: Vitiligo Drug Safety and Effectiveness Registry for Adults and Teens

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, observational registry enrolling adolescents and adults with nonsegmented vitiligo under dermatology care. It aims to build a cohort to observe long-term safety and effectiveness of standard of care treatments for NSV in real-world settings. Data collected may address disease natural history, medication effectiveness and safety, and regulatory risk–benefit context, as well as drug use, disease burden, and unmet needs. Participation depends on confirmed NSV diagnosis, age 12 or older, consent/assent, and enrollment in one of two cohorts based on current or anticipated medication use. The study is led by Cor Evitas with locations at CorEvitas, LLC in Waltham, MA.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Individuals are eligible for enrollment if they meet all of the following criteria:

* Have a dermatologist- or qualified dermatology practitioner-confirmed diagnosis of nonsegmental vitiligo (NSV).
* Is at least 12 years of age or older at the time of enrollment.
* Is willing and able to provide informed consent or assent, with parent/legal guardian consent as applicable.
* Adult participants are willing and able to provide required personal information

  • Full legal name, sex, date of birth, and home ZIP/postal code
* Meet the criteria for one of the following enrollment cohorts at the time of enrollment:

Cohort 1: Eligible Medication Initiators - Individuals initiating a prescribed eligible NSV medication at the time of enrollment.

Cohort 2: Not Initiating Eligible Medication - Individuals not currently receiving NSV medication at the time of enrollment, Individuals receiving eligible NSV medication prior to enrollment.

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in the registry:

\- Is participating or planning to participate in a blinded clinical trial for a vitiligo therapy.

Where it's running

• CorEvitas, LLC
  Waltham, Massachusetts, United States Recruiting

Study contacts

• Study coordinator: Vitiligo Registry Study Team
• Email: VITregistry@thermofisher.com
• Phone: 508-408-5531

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• crisaborole 2% versus tacrolimus 0.1% with light therapy for facial vitiligo

  This study tests whether applying crisaborole 2% ointment can improve stable facial vitiligo in children and adults and whether it is as safe and effective as tacrolimus 0.1% when combined with light therapy.

  Recruiting Phase 3 Cairo University · Cairo · NCT07904910

• Imaging vitiligo lesions with polarized, sub-ultraviolet, and ultraviolet dermoscopy

  This study tests whether advanced light-based skin imaging can reveal details of vitiligo spots in adults more clearly than standard polarized dermoscopy.

  Recruiting Istanbul Training and Research Hospital · Istanbul · NCT07846969

• MH004 Ointment in non-segmental vitiligo: a phase 3 trial

  A 12-month randomized trial tests MH004 ointment to see if it helps facial vitiligo more than a placebo in people aged 12 to 75.

  Recruiting Phase 3 Minghui Pharmaceutical (Hangzhou) Ltd · Beijing, Beijing Municipality · NCT07682506

• D-2570 in Non-Segmental Vitiligo (Phase 2)

  This study tests whether D-2570 can improve skin discoloration in adults with non-segmental vitiligo compared with a placebo.

  Recruiting Phase 2 InventisBio Co., Ltd · Shanghai, Shanghai Municipality · NCT07625891

• LY4005130 for adults with non-segmental vitiligo

  This study will test whether intravenous LY4005130 is safe and what side effects it may cause in adults with non-segmental vitiligo.

  Recruiting at 35 sites Phase 2 Eli Lilly and Company · Phoenix, Arizona and 34 other locations · NCT07533019

• Micro-needling with 5‑fluorouracil versus strong topical steroid for limited vitiligo

  This trial will test whether micro-needling plus 5‑fluorouracil or a potent topical steroid works better to restore pigment in people with limited, stable vitiligo.

  Recruiting Early Phase 1 Combined Military Hospital (CMH) institute of Medical Sciences Bahawalpur Pakistan · Chak Eighty-seven -Twelve Left · NCT07398807

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.